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is enhanced following interaction with
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Abstract
Background: Macrophages are the dominant phagocyte at sites of wound healing and inflammation, and the
cellular and acellular debris encountered by macrophages can have profound effects on their inflammatory profile.
Following interaction with apoptotic cells, macrophages are known to switch to an anti-inflammatory phenotype.
Activated platelets, however, are also a major component of inflammatory lesions and have been proposed to be
pro-inflammatory mediators. In the present study, we tested the hypothesis that macrophage interaction with
activated platelets results in an inflammatory response that differs from the response following phagocytosis of
apoptotic cells.
Methods: Human monocyte-derived macrophages (hMDMs) were co-incubated with autologous activated
platelets (AAPs) and the platelet-macrophage interaction was examined by electron microscopy and flow
cytometry. The cytokines TNF-a, IL-6, and IL-23 were also measured during LPS-activated hMDM co-incubation with
AAPs, which was compared to co-incubation with apoptotic lymphocytes. Cytokine secretion was also compared
to platelets pre-treated with the gluococorticoid dexamethasone.
Results: Macrophages trapped and phagocytized AAPs utilizing a mechanism that was significantly inhibited by
the scavenger receptor ligand fucoidan. LPS-induced macrophage secretion of TNF-a, IL-6, and IL-23 was inhibited
by co-incubation with apoptotic cells, but enhanced by co-incubation with AAPs. The platelet-dependent
enhancement of LPS-induced cytokines could be reversed by pre-loading the platelets with the glucocorticoid
dexamethasone.
Conclusions: The interaction of human macrophages with autologous platelets results in scavenger-receptor-
mediated platelet uptake and enhancement of LPS-induced cytokines. Therefore, the presence of activated
platelets at sites of inflammation may exacerbate pro-inflammatory macrophage activation. The possibility of
reversing macrophage activation with dexamethasone-loaded platelets is a promising therapeutic approach to
treating unresolved inflammation.
Background
A major function of macrophages is phagocytosis of cel-
lular and acellular debris during inflammation and
wound healing, and the activation response of macro-
phages following phagocytosis can be varied depending
on the local extracellular environment [1-6]. The impor-
tance of phagocytosis in the resolution of inflammation
is emphasized by pathological conditions involving
impaired phagocytosis, which may manifest as persistent
infections or chronic inflammatory lesions such as dia-
betic ulcers and atherosclerotic plaques [7-11].
During their differentiation from primary monocytes,
macrophages acquire specialized receptors and machin-
ery for recognizing and clearing both apoptotic and
infected cells [12]. In clearing apoptotic cells, macro-
phages use receptors such as scavenger receptors and
integrins that function independently or in cooperation
with each other depending on the type of cell targeted
for phagocytosis [13-19].
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Platelets are anucleate cells which play an integral role
in maintaining vascular integrity. Within their 8-10 day
lifespan, platelets can become activated either in the cir-
culation or during adherence at a site of injury, and dur-
ing this process they become targeted for destruction by
macrophages [20]. The process of platelet activation
involves several changes to the cell surface, including
expression of P-selectin and loss of membrane asymme-
try [21-23]. These changes in the platelet membrane
may provide molecular signals to macrophages that trig-
ger phagocytosis, although the precise mechanism by
which macrophages recognize and phagocytose activated
platelets remains to be identified.
Cells that have become apoptotic as part of their nor-
mal life cycle are recognized and cleared by phagocyto-
sis in a manner that usually inhibits pro-inflammatory
responses [24-27]. Although circulating platelets can
exert a pro-inflammatory effect on circulating mono-
cytes [28,29], their effect on differentiated macrophages,
particularly at sites of inflammation, is not clear. We
show here that phagocytosis of autologous platelets
results in an pro-inflammatory profile that is opposite to
the macrophage response following phagocytosis of
apoptotic cells. Importantly, the platelet-enhanced, pro-
inflammatory response of macrophages can be inhibited
when the platelets are loaded with the glucocorticoid
dexamethasone. In addition to novel insight into the
macrophage inflammatory profile that exists in several
diseases, these results also provide evidence that plate-
let-macrophage interactions are an important therapeu-
tic target for reducing inflammation.
Methods
Monocyte-derived Macrophages
Human monocytes were isolated and cultured using
techniques similar to those previously described [30,31].
Briefly, blood from healthy human donors was collected
into citrate and peripheral blood mononuclear cells
(PBMCs) were isolated by using Lymphoprep (Accurate
Chemical) according to the manufacturer’s instructions.
Monocytes were further isolated by plating the PBMCs
on gelatin-coated tissue culture flasks for 45 min at 37°C
followed by 10 washes with phosphate buffered saline
(PBS) to remove non-adherent lymphocytes. Monocytes
were then detached from the flasks by incubation in 10
mM EDTA for 2 min at 37°C. Monocytes (250,000 in 500
μl volume) were then plated in 24-well plates overnight
in RPMI 1640 supplemented with 10% fetal bovine
serum (FBS) and 10 ng/ml recombinant human GM-CSF
(R&D Systems). Monocytes were plated on glass cover-
slips for scanning electron microscopy (SEM) analysis
and plastic tissue-culture plates for TEM analysis and
phagocytosis experiments. Media was changed on day 2
and day 5, and after 7 days of culture the MDMs were
used for phagocytosis and cytokine assays.
Platelets
Platelets were isolated from whole blood collected into
acid-citrate-dextrose (ACD) from healthy human donors
and centrifuged for 15 min at 500 × g to generate plate-
let-rich plasma (PRP). PRP was pelleted by centrifugation
for 10 min at 800 × g and the platelet pellet subsequently
washed 2 times in citrated saline (pH 6.8). A portion of
the platelet samples were degranulated by incubating
1 ml of platelets (250,000/μl in citrated saline) with 10 μl
of 10 μM calcium ionophore A21387 (Sigma) for 15 min
with rocking at room temperature, followed by three cen-
trifugational washes with citrated saline. For phagocytosis
experiments, platelets were fluorescently labeled with
Cell Tracker Green CMFDA (Invitrogen) as previously
described [32]. After the final wash, and prior to use in
phagocytosis assays, platelets were resuspended in warm
serum-free RPMI for 15 min at 37°C.
For analysis of surface P-selectin and phosphatidylserine,
platelets (250,000/μl) were first incubated in either citrated
saline or serum-free RMPI media for 1 hr at 37°C. A por-
tion of the platelets were activated by including thrombin
(King Pharmaceuticals, 1 U/ml final concentration) in the
incubation reaction. To detect surface expression of acti-
vation markers in each platelet treatment group, a 10 μl
aliquot of platelets was stained with either FITC-anti-
CD62P (Biolegend) or FITC-Annexin-V (Biolegend) for
30 min at room temperature, after which the cells were
fixed and analyzed immediately by flow cytometry. Flow
cytometry analysis was performed using a CyAn flow cyt-
ometer (Beckman Coulter) and the Summit analysis
software.
Dexamethasone-loaded platelets were prepared by
incubating 1 ml of platelets (250,000/ul) in citrated saline
with 5 ul of dexamethasone (Sigma, 10 mM in DMSO)
for 15 min on a rocker at room temperature. Platelets
were then washed three times with citrated saline to
remove unbound dexamethasone. For subsequent experi-
ments, 5 × 106 dex-platelets were added to each well of
macrophages in a 24-well plate.
To prepare apoptotic cells, PBMCs were isolated as
above, and following monocyte-adherence to gelatin-
coated flasks the non-adherent lymphocytes were
collected. Cells were rendered apoptotic (Annexin-V
positive) by UV-irradiation for 10 min followed by over-
night incubation in RPMI + 10% FBS at 37°C + 5% CO2.
Phagocytosis Experiments
Thirty minutes prior to the start of each experiment, 7-day
old MDMs were washed 3 times with PBS and incubated
with 500 μl fresh RPMI media. In some experiments the
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media was supplemented with 10% autologous human
serum. A 25 μl aliquot of fluorescently labeled platelets
(250,000/μl) was added to each well of macrophages. Pla-
telets and macrophages were co-incubated for 45 min.
For SEM analysis, the co-cultures were washed once
with PBS and fixed in 2% paraformaldehyde and 0.5%
glutaraldehyde. The samples were then processed as
previously described [33] and examined using a Cam-
bridge S200 scanning electron microscope at 20 kV. For
TEM analysis, the co-cultures were washed 5 times with
PBS and fixed in 2% paraformaldehyde, processed as
previously described [34], and examined using a Leo EM
910 transmission electron microscope. For flow cyto-
metric analysis, warm trypsin/EDTA was then added to
the macrophages to remove adherent platelets (con-
firmed by microscopy) and cells were incubated 15 min
at 37°C. Macrophages were then collected and fixed in
1% cold paraformaldehyde and analyzed using a CyAn
flow cytometer (Beckman Coulter) and the Summit ana-
lysis software. Data is expressed as the percentage of
FL1-positive macrophages in a given collection of
10,000 macrophages. Data shown represent the average
of at least 3 independent experiments and for each
experiment 10,000 macrophages were analyzed.
Latrunculin (Sigma, 1 μg/ml final concentration), used
as a pan-phagocytosis inhibitor, was added to a portion of
macrophage-containing wells 30 min prior to addition of
platelets. Fucoidan (Sigma) was added to macrophages at a
final concentration of 250 μg/ml 30 min prior to addition
of platelets.
Cytokine Experiments
Each well of MDMs was washed 3 times with PBS and
incubated with fresh RPMI + 10% autologous human
serum. Activated, degranulated, or dexamethasone-
loaded platelets (5 × 106) were added to each well in
addition to LPS (100 ng/ml). Some samples also received
dexamethasone alone at a final concentration of 1 μM.
After 24 hrs, supernatants were collected, spun 10 min at
14,000 g, and frozen at -80°C. Cytokines were measured
by ELISA using capture and detection antibodies
(eBioscience) per the manufacturer’s instructions. Cyto-
kines were measured in duplicate and averaged. The
amount of protein secreted was normalized to the
amount secreted by macrophages treated with LPS alone.
Each experiment was performed at least 3 times using 3
different MDM donors. In each experiment, the platelets
added were from the same donor as the MDMs. Treat-
ment groups were compared using an unpaired t-test.
Results
Macrophage Phagocytosis of Autologous Platelets
To examine the interaction between human MDMs
(hMDMs) and autologous platelets, we utilized an
in vitro co-culture system consisting of 7-day old
hMDMs to which we added freshly isolated autologous
platelets. The use of autologous platelets excludes the
possibility that platelet-macrophage interactions are the
result of an immune response triggered by the recogni-
tion of platelets as ‘foreign.’ The hMDMs and platelets
were first co-cultured in serum-free RPMI media and
examined by SEM and TEM at various time points to
visualize the interaction between these two different cell
types. As shown in Figure 1A, we observed platelets
interacting with hMDMs during the first hour of co-
culture. Platelets near the macrophages became
entrapped by a network of macrophage filopodia, and
although the macrophages were firmly attached to the
coverslip and did not migrate, they appeared to direct
groups of filopodia in the direction of nearby platelets
that had settled on the dish. Visualization of these cul-
tures suggests that an interaction between human
macrophages and autologous activated platelets (AAPs)
occurs in vitro, and that it occurs in the absence of
serum proteins.
Platelet phagocytosis by the macrophages in our co-
culture system was subsequently confirmed by TEM and
flow cytometry. Macrophages that were co-incubated
with AAPs for one hour developed vacuoles, many of
which contained contents that were the same size and
shape as platelets (Figure 1B). These phagocytic vacuoles
did not appear in control macrophages cultured in the
absence of platelets. We then quantified phagocytosis by
flow cytometric analysis of macrophage fluorescence
after co-incubation with fluorescently labeled platelets
and removal of adherent platelets with trypsin. When
freshly isolated platelets were incubated in serum-free
RPMI media and added in excess to 7-day old macro-
phages, approximately 50% of the macrophages interna-
lized at least one platelet within 45 min (Figure 2). As
expected, pretreatment of the hMDMs with the actin
inhibitor latrunculin almost completely blocked phagocy-
tosis, confirming the role of actin polymerization that
occurs in all cases of phagocytosis (Figure 2A). The
amount of phagocytosis increased if the platelets were
pre-stimulated with thrombin (Figure 2B), and was signif-
icantly inhibited in the presence of fucoidan, a known
competitive inhibitor to Scavenger Receptors [35,36]
(Figure 2C). The presence of 10% autologous human
serum had no significant effect on phagocytosis, which
excludes the possibility that the platelet-macrophage
interaction requires a soluble serum-bound “bridging”
molecule. Together these results suggest that phagocyto-
sis of platelets correlates with platelet activation, and that
macrophage phagocytosis of autologous platelets may be
mediated, at least in part, by scavenger receptors.
We also used flow cytometry to more accurately exam-
ine the level of platelet activation in different culture
Scull et al. Journal of Inflammation 2010, 7:53
http://www.journal-inflammation.com/content/7/1/53
Page 3 of 9
conditions. Platelets were analyzed for expression of
P-selectin, an alpha granule component expressed during
early platelet activation, and phosphatidylserine, a mem-
brane lipid exposed on the surface of completely (and irre-
versibly) activated platelets. Incubation in serum-free
media alone for 1 hour resulted in an approximately ten-
fold increase in P-selectin expression but did not induce
surface expression of phosphatidylserine (Table 1). Treat-
ment of platelets with thrombin, known to cause complete
degranulation and irreversible platelet activation [23,37],
resulted in even higher levels of P-selectin and also
increased surface expression of phosphatidylserine (Table
1). Interestingly, the data in Figures 1 and 2 showing pha-
gocytosis of platelets incubated only in RPMI media
suggests that only partial platelet activation, in the absence
of complete degranulation or phosphatidylserine exposure,
is sufficient to trigger phagocytosis. Although phagocytosis
was enhanced when the platelets did express phosphatidyl-
serine, we conclude that surface exposure of phosphatidyl-
serine is not an absolute requirement for phagocytosis of
platelets.
Inflammatory Cytokines are Enhanced Following
Platelet Phagocytosis
The hypothesis that macrophage phagocytosis of acti-
vated platelets results in an inflammatory response that
differs from the response following phagocytosis of
apoptotic cells was tested by measuring the secretion of
Figure 1 Electron Microscopic Analysis of Platelet-Macrophage Interactions. (A) hMDMs were incubated with fresh AAPs for 15 min (left
panel) or 45 min (right panel) before processing for SEM analysis. (B) TEM analysis of hMDMs after 1 hr co-incubation with platelets. Arrow
indicates phagocytic vacuole at high magnification.
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cytokines following addition of platelets or apoptotic
cells to LPS-stimulated hMDMs. Autologous platelets
in two different activation states were used in the co-
culture experiments: platelets that were “partially acti-
vated” (with surface exposure of measurable quantities
of P-selectin and CD40L) by preparing in serum-free
media or “irreversibly activated” (with phosphatidylser-
ine exposure in addition to P-selectin) by treatment
with the calcium ionophore A23187 [37].
The inflammatory response of the hMDMs was assessed
by measuring the levels of TNF-a, IL-6, and IL-23 after
incubation with autologous primed platelets, autologous
activated platelets, or control apoptotic leukocytes in the
presence of LPS for 24 hours. As an additional control, we
analyzed “platelets-only” cultures using the same media
and incubation times as the platelet-macrophage co-cul-
tures and were unable to detect any TNF-a, IL-6, or IL-23
in platelets alone (with or without LPS, data not shown).
We therefore conclude that the cytokines secreted in this
system are macrophage-derived, and in each experiment
the cytokine levels were normalized to the amount of cyto-
kine secreted by hMDMs incubated with LPS alone.
When compared to LPS stimulation alone, macro-
phage co-incubation with apoptotic cells inhibited
LPS-induced secretion of all three pro-inflammatory
cytokines (Figure 3A, grey bars). However, co-incubation
with primed or activated platelets enhanced macrophage
secretion of TNF-a, IL-6, and IL-23. Induction of pro-
inflammatory cytokines in the presence of platelets was
20-60% higher than the levels obtained by LPS treat-
ment alone. Furthermore, the macrophage cytokine
secretion was enhanced to a similar degree after co-
incubation with both partially activated and degranu-
lated platelets (Figure 3A). These data suggest activated
platelets enhance LPS-induced macrophage cytokine
secretion even when they present phosphatidylserine to
the macrophage.
Based on the knowledge that platelets can bind gluco-
corticoids via glucocorticoid receptors [38], we tested the
hypothesis that glucocorticoid-bound platelets would be
less inflammatory than platelets that are activated, but
otherwise unmodified. Platelets were incubated with dex-
amethasone, then unbound glucocorticoid was removed
by washing the platelets in citrated saline. Although it is
Figure 2 Flow Cytometric Analysis of Platelet Phagocytosis.
hMDMs were incubated with an excess of fluorescently labeled
platelets for 45 min in RPMI media alone (white bars) or containing
10% autologous human serum (striped bars). Macrophage
fluorescence was measured by flow cytometry and the average
percentage of FL1-positive macrophages after removal of adherent
platelets are shown for 3 independent experiments for each sample.
Data for control samples are repeated in each panel, and compared
to treatment with (A) latrunculin (1 ug/ml), (B) thrombin (0.1 U/ml),
or (C) fucoidan (250 ug/ml). Statistically significant differences are
indicated with their corresponding p-values. The addition of 10%
serum did not result in any statistically significant difference (NS).
Table 1 Platelet Activation in Co-Culture Conditions
P-selectin Phosphatidylserine
citrated saline control 15.2 +/- 3.0 8.9 +/- 0.9
RPMI 1 hour 178.5 +/- 33.1 11.3 +/- 3.1
thrombin 1471.3 +/- 155.8 1599.9 +/- 464.5
Platelets were analyzed for platelet activation markers by flow cytometry as
described in Methods. Values are expressed as Mean Fluorescence Intensity,
and are the averages (+/- standard error) of at least 3 independent
experiments.
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unlikely that all of the dexamethasone becomes bound to
the platelets, complete retention of the dexamethasone
would yield a final concentration in the DEX-plt stock of
50 μM and a final (effective) concentration in the plate-
let-macrophage co-cultures of 1 μM. As shown in Figure
3B (striped bars), the levels of cytokines produced after
co-culture with dexamethasone-loaded platelets were
inhibited to 30-50% of the levels produced by stimulation
with LPS alone. The dexamethasone-loaded platelets had
a similar effect on cytokine secretion as 1 μM dexa-
methasone alone. These results indicate that the pro-
inflammatory platelet effect on macrophage activation
can be reversed by pre-loading the platelets with
glucocorticoids.
Discussion
Phagocytosis is an important means of clearing both
immunologically compromised and apoptotic cells.
Monocyte-derived macrophages are efficient phagocytes
in organs of the reticuloendothelial system and within
injured tissues; however, the process of platelet clear-
ance by macrophages is poorly understood. This work
has demonstrated phagocytosis of fresh autologous acti-
vated platelets (AAPs) by monocyte-derived macro-
phages using an entirely human-derived in vitro system.
In this system, uptake of freshly isolated platelets is
dependent on actin polymerization, but occurs indepen-
dently of any soluble serum factors. Additionally, phago-
cytosis of platelets is enhanced with platelet activation.
Previous studies on platelet phagocytosis have focused
on modified platelets such as chilled platelets, opsonized
platelets, and aged platelets [39-46], each of which
involves distinct changes to the platelet surface. Aged
platelets most closely resemble freshly activated platelets
because during aging platelets increase expression of
phosphatidylserine and P-selectin [20]. Interestingly,
Brown et al. have also shown in vitro that phagocytosis of
aged platelets is mediated by scavenger receptors [20].
Figure 3 Cytokine analysis of macrophages in the presence of activated platelets, apoptotic cells, and dexamethasone. Cytokines were
measured by ELISA 24 hrs after stimulation with LPS (100 ng/ml) in the presence or absence of (A) apoptotic cells or platelets, and (B)
dexamethasone alone (1 μM) or dexamethasone-loaded platelets. Data for activated platelets is repeated in both panels. Cytokine levels are
expressed relative to treatment with LPS only. Macrophages were incubated with equivalent numbers of platelets in each condition. Shown are
the averages of at least 3 independent experiments. Statistically significant differences are indicated with corresponding p-values.
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Therefore, macrophages may recognize freshly activated
platelets in the same way that they clear aged platelets.
The finding that phosphatidylserine exposure is not a
requirement for phagocytosis of AAPs in the present
study was somewhat unexpected, considering that phos-
phatidylserine is a well documented ‘eat me’ signal for
the phagocytosis of many different types of cells under-
going apoptosis [47-50].
Because phagocytosis correlates with platelet activation,
we would expect no phagocytosis to occur in the pre-
sence of quiescent platelets. However, RPMI media alone
causes platelet activation (Table 1), probably due to the
presence of low levels of calcium and phosphate. Addi-
tionally, the use of platelet inhibitors such as aspirin,
EDTA, or prostaglandin, which may have maintained the
platelets in a resting state, could not be used because
they directly affect macrophage function [51,52]. Thus,
one disadvantage of our system is that the platelet-
macrophage interaction using activated platelets could
not be compared to an interaction in which the platelets
were in a truly resting state. Nonetheless, the interaction
involving activated platelets is relevant because platelets
are most likely activated at sites of tissue injury and per-
haps during removal in the spleen. Thus, the interaction
involving activated platelets was the focus of this work.
The macrophage response following phagocytosis of
cells expressing surface phosphatidylserine is usually
immunosuppressive [2,26,27,53,54]. In the present study,
co-culture with apoptotic cells inhibited production of
pro-inflammatory cytokines by LPS-activated macro-
phages. These results are in agreement with previous find-
ings for TNF-a, IL-1b, IL-8, IL-12 [2,4,55,56], and are
extended to now include IL-6 and IL-23.
In contrast to the effect of apoptotic cells, activated pla-
telets enhanced pro-inflammatory cytokine secretion
from LPS-activated macrophages. The cytokines mea-
sured in the current study, TNF-a, IL-6 and IL-23, are
significant readouts because they are known to be
secreted by macrophages, but not platelets, and they play
important roles in mediating pro-inflammatory
responses. Interestingly, the pro-inflammatory cytokine
secretion was also enhanced by platelets with surface
phosphatidylserine exposure. The finding that degranu-
lated platelets, washed free from their secreted proteins,
also enhanced LPS-induced macrophage cytokine secre-
tion suggests that a secreted platelet factor is not likely to
be responsible for this effect. However, a secreted platelet
factor could exert the observed effect if it remained
bound to the platelet surface after secretion from the pla-
telet. Because the platelets remained in the co-incubation
for the entire experiment (24 hrs), the possibility also
exists that the inflammatory consequences of platelet-
macrophage interactions occur independently of phago-
cytosis. Cell contact itself could be responsible for the
observed effects. Nonetheless, we have shown the pro-
inflammatory effect of platelets does occur in conditions
which favor platelet uptake (Figure 1).
Recent studies have highlighted additional roles of plate-
lets beyond hemostasis, particularly with respect to plate-
let-mediated effects on inflammation [28,57,58]. These
results are particularly relevant to chronic inflammatory
diseases, during which macrophages may interact with
apoptotic or necrotic cells, as well as platelets, for pro-
longed periods of time. Studies in mice have demonstrated
that depletion of platelets or platelet proteins affects
macrophage infiltration and inflammation in lesions of the
skin, joints, gut, and vasculature [59-63]. Although the
precise mechanisms by which platelets impact macro-
phage activation remain unclear, the current study pro-
vides direct evidence, using human cells, of specific
macrophage cytokines that are enhanced by activated
platelets.
Pro-inflammatory cytokines secreted by macrophages
can also exert effects on surrounding cells and tissues. For
example, IL-6 and IL-23 stimulate T-cells for induction of
Th17 immune responses, which are operant in autoim-
mune diseases such as inflammatory bowel disease, lupus,
psoriasis and arthritis [64-67]. We speculate, therefore,
that in addition to amplifying general pro-inflammatory
responses, platelet-macrophage interactions might also
play a role in Th17-mediated autoimmune diseases.
Glucocorticoids such as dexamethasone can exert
powerful immunosuppressive effects on leukocytes and
are thus an attractive therapy for modulating inflamma-
tion [68]. After steroid binding to glucocorticoid recep-
tors, which occurs within the cytoplasm, activated
glucocorticoid receptors translocate to the nucleus and
inhibit transcription of a variety of pro-inflammatory
cytokines [68]. We speculate, therefore, that the immu-
nosuppressive action of dexamethasone-loaded platelets
occurs by facilitating delivery of dexamethasone to
macrophage glucocorticoid receptors. Because macro-
phage glucocorticoid receptors are cytoplasmic, we
further speculate that the immunosuppressive effect of
dex-platelets is a result of phagocytosis. The use of dexa-
methasone-loaded platelets for modulating macrophage
action may prove useful in treating diseases characterized
by excessive and unresolving inflammation. Our results
demonstrating similar levels of immunosuppression with
both free dexamethasone and dexamethasone bound to
platelets suggests that tethering glucocorticoids to plate-
lets may increase drug targeting and reduce the need for
high systemic doses of glucocorticoids, which can have
unwanted side effects [69]. Furthermore, given the role of
IL-6 and IL-23 in Th17-mediated inflammatory
responses, the platelet-macrophage interaction is there-
fore a rational pharmacological target for inhibiting some
Th17-related diseases.
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Conclusions
We have shown here that the interaction of human
macrophages with autologous platelets results in scaven-
ger-receptor-mediated platelet uptake and enhancement
of LPS-induced cytokine secretion. Given the presence of
activated platelets together with macrophages during the
response to injury and during inflammation, activated
platelets at sites of inflammation most likely exacerbate
the macrophage response. The presence of platelets must
therefore be carefully considered when studying the cel-
lular interactions occurring in inflammatory lesions.
We have also presented evidence here that platelets
can be engineered to exert anti-inflammatory effects on
macrophages. Given the emerging role of platelets in
inflammatory diseases, the possibility of reversing
macrophage activation with dexamethasone-loaded pla-
telets is a promising therapeutic approach to treating
unresolved inflammation.
Acknowledgements
This work was supported by sponsored research funds from Entegrion, Inc.
(Research Triangle Park, NC, USA) and a collaborative research grant from
the North Carolina Biotechnology Center.
Authors’ contributions
CMS conceived of the study, participated in its design and coordination,
performed phagocytosis assays and cytokine measurements, and drafted the
manuscript. WDH participated in the design of the study, coordinated the
selection and participation of blood donors, and processed the blood
samples. THF was the principal investigator on this project and provided
guidance and advice on the experiments and manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 June 2010 Accepted: 11 November 2010
Published: 11 November 2010
References
1. Aderem A: Phagocytosis and the inflammatory response. J Infect Dis 2003,
187(Suppl 2):S340-345.
2. Chung EY, Kim SJ, Ma XJ: Regulation of cytokine production during
phagocytosis of apoptotic cells. Cell Res 2006, 16:154-161.
3. Birge RB, Ucker DS: Innate apoptotic immunity: the calming touch of
death. Cell Death Differ 2008, 15:1096-1102.
4. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM:
Macrophages that have ingested apoptotic cells in vitro inhibit
proinflammatory cytokine production through autocrine/paracrine
mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998, 101:890-898.
5. Li Y, Gerbod-Giannone MC, Seitz H, Cui D, Thorp E, Tall AR, Matsushima GK,
Tabas I: Cholesterol-induced apoptotic macrophages elicit an
inflammatory response in phagocytes, which is partially attenuated by
the Mer receptor. J Biol Chem 2006, 281:6707-6717.
6. Henson PM, Hume DA: Apoptotic cell removal in development and tissue
homeostasis. Trends Immunol 2006, 27:244-250.
7. Rosqvist R, Bolin I, Wolf-Watz H: Inhibition of phagocytosis in Yersinia
pseudotuberculosis: a virulence plasmid-encoded ability involving the
Yop2b protein. Infect Immun 1988, 56:2139-2143.
8. Casanova JL, Abel L: Revisiting Crohn’s disease as a primary
immunodeficiency of macrophages. J Exp Med 2009, 206:1839-1843.
9. Oncul O, Yildiz S, Gurer US, Yeniiz E, Qyrdedi T, Top C, Gocer P, Akarsu B,
Cevikbas A, Cavuslu S: Effect of the function of polymorphonuclear
leukocytes and interleukin-1 beta on wound healing in patients with
diabetic foot infections. J Infect 2007, 54:250-256.
10. Maree AF, Komba M, Finegood DT, Edelstein-Keshet L: A quantitative
comparison of rates of phagocytosis and digestion of apoptotic cells by
macrophages from normal (BALB/c) and diabetes-prone (NOD) mice. J
Appl Physiol 2008, 104:157-169.
11. Tabas I: Consequences and therapeutic implications of macrophage
apoptosis in atherosclerosis: the importance of lesion stage and
phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005, 25:2255-2264.
12. Mukhopadhyay S, Pluddemann A, Gordon S: Macrophage pattern
recognition receptors in immunity, homeostasis and self tolerance. Adv
Exp Med Biol 2009, 653:1-14.
13. Albert ML, Kim JI, Birge RB: alphavbeta5 integrin recruits the CrkII-
Dock180-rac1 complex for phagocytosis of apoptotic cells. Nat Cell Biol
2000, 2:899-905.
14. Fadok VA, Savill JS, Haslett C, Bratton DL, Doherty DE, Campbell PA,
Henson PM: Different populations of macrophages use either the
vitronectin receptor or the phosphatidylserine receptor to recognize
and remove apoptotic cells. J Immunol 1992, 149:4029-4035.
15. Fadok VA, Warner ML, Bratton DL, Henson PM: CD36 is required for
phagocytosis of apoptotic cells by human macrophages that use either
a phosphatidylserine receptor or the vitronectin receptor (alpha v beta
3). J Immunol 1998, 161:6250-6257.
16. Gregory CD: CD14-dependent clearance of apoptotic cells: relevance to
the immune system. Curr Opin Immunol 2000, 12:27-34.
17. Hart SP, Dransfield I, Rossi AG: Phagocytosis of apoptotic cells. Methods
2008, 44:280-285.
18. Platt N, Suzuki H, Kurihara Y, Kodama T, Gordon S: Role for the class A
macrophage scavenger receptor in the phagocytosis of apoptotic
thymocytes in vitro. Proc Natl Acad Sci USA 1996, 93:12456-12460.
19. Savill J, Fadok V, Henson P, Haslett C: Phagocyte recognition of cells
undergoing apoptosis. Immunol Today 1993, 14:131-136.
20. Brown SB, Clarke MC, Magowan L, Sanderson H, Savill J: Constitutive death
of platelets leading to scavenger receptor-mediated phagocytosis. A
caspase-independent cell clearance program. J Biol Chem 2000,
275:5987-5996.
21. Andre P: P-selectin in haemostasis. Br J Haematol 2004, 126:298-306.
22. Zwaal RF, Bevers EM: Platelet phospholipid asymmetry and its
significance in hemostasis. Subcell Biochem 1983, 9:299-334.
23. Heemskerk JW, Bevers EM, Lindhout T: Platelet activation and blood
coagulation. Thromb Haemost 2002, 88:186-193.
24. Djaldetti M, Salman H, Bergman M, Djaldetti R, Bessler H: Phagocytosis–the
mighty weapon of the silent warriors. Microsc Res Tech 2002, 57:421-431.
25. Ravichandran KS, Lorenz U: Engulfment of apoptotic cells: signals for a
good meal. Nat Rev Immunol 2007, 7:964-974.
26. Gregory CD, Devitt A: The macrophage and the apoptotic cell: an innate
immune interaction viewed simplistically? Immunology 2004, 113:1-14.
27. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I:
Immunosuppressive effects of apoptotic cells. Nature 1997, 390:350-351.
28. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM,
French PA, Dauerman HL, Becker RC: Platelet functions beyond
haemostasis. J Thromb Haemost 2009, 7(11):1759-66.
29. Weyrich AS, Lindemann S, Zimmerman GA: The evolving role of platelets
in inflammation. J Thromb Haemost 2003, 1:1897-1905.
30. Jones BM, Nicholson JK, Holman RC, Hubbard M: Comparison of monocyte
separation methods using flow cytometric analysis. J Immunol Methods
1989, 125:41-47.
31. Hassan NF, Campbell DE, Douglas SD: Purification of human monocytes
on gelatin-coated surfaces. J Immunol Methods 1986, 95:273-276.
32. Baker GR, Sullam PM, Levin J: A simple, fluorescent method to internally
label platelets suitable for physiological measurements. Am J Hematol
1997, 56:17-25.
33. Fischer TH, Robbins ME, Bode AP, Nichols TC, Bellinger DE, Schoenfisch MH:
Evidence that rehydrated, lyophilized red blood cells are sufficiently
deformable for normal microcirculation transit. Microsc Res Tech 2004, 65:62-71.
34. Sanders WE, Read MS, Reddick RL, Garris JB, Brinkhous KM: Thrombotic
thrombocytopenia with von Willebrand factor deficiency induced by
botrocetin. An animal model. Lab Invest 1988, 59:443-452.
35. Nakamura T, Suzuki H, Wada Y, Kodama T, Doi T: Fucoidan induces nitric
oxide production via p38 mitogen-activated protein kinase and NF-
Scull et al. Journal of Inflammation 2010, 7:53
http://www.journal-inflammation.com/content/7/1/53
Page 8 of 9
kappaB-dependent signaling pathways through macrophage scavenger
receptors. Biochem Biophys Res Commun 2006, 343:286-294.
36. Krieger M, Herz J: Structures and functions of multiligand lipoprotein
receptors: macrophage scavenger receptors and LDL receptor-related
protein (LRP). Annu Rev Biochem 1994, 63:601-637.
37. White JG, Rao GH, Gerrard JM: Effects of the lonophore A23187 on blood
platelets I. Influence on aggregation and secretion. Am J Pathol 1974,
77:135-149.
38. Moraes LA, Paul-Clark MJ, Rickman A, Flower RJ, Goulding NJ, Perretti M:
Ligand-specific glucocorticoid receptor activation in human platelets.
Blood 2005, 106:4167-4175.
39. Hoffmeister KM, Felbinger TW, Falet H, Denis CV, Bergmeier W, Mayadas TN,
von Andrian UH, Wagner DD, Stossel TP, Hartwig JH: The clearance
mechanism of chilled blood platelets. Cell 2003, 112:87-97.
40. Badlou BA, Spierenburg G, Ulrichts H, Deckmyn H, Smid WM, Akkerman JW:
Role of glycoprotein Ibalpha in phagocytosis of platelets by
macrophages. Transfusion 2006, 46:2090-2099.
41. Badlou BA, Wu YP, Smid WM, Akkerman JW: Platelet binding and
phagocytosis by macrophages. Transfusion 2006, 46:1432-1443.
42. Josefsson EC, Gebhard HH, Stossel TP, Hartwig JH, Hoffmeister KM: The
macrophage alphaMbeta2 integrin alphaM lectin domain mediates the
phagocytosis of chilled platelets. J Biol Chem 2005, 280:18025-18032.
43. Babic AM, Josefsson EC, Bergmeier W, Wagner DD, Kaufman RM,
Silberstein LE, Stossel TP, Hartwig JH, Hoffmeister KM: In vitro function and
phagocytosis of galactosylated platelet concentrates after long-term
refrigeration. Transfusion 2007, 47:442-451.
44. Bondanza A, Sabbadini MG, Pellegatta F, Zimmermann VS, Tincani A,
Balestrieri G, Manfredi AA, Rovere P: Anti-beta2 glycoprotein I antibodies
prevent the De-activation of platelets and sustain their phagocytic
clearance. J Autoimmun 2000, 15:469-477.
45. Roubey RA: Immunology of the antiphospholipid syndrome: antibodies,
antigens, and autoimmune response. Thromb Haemost 1999, 82:656-661.
46. Roubey RA: Systemic lupus erythematosus, hypercoagulable states, and
antiphospholipid antibodies. Arthritis Care Res 1999, 12:155-156.
47. Wu Y, Tibrewal N, Birge RB: Phosphatidylserine recognition by
phagocytes: a view to a kill. Trends Cell Biol 2006, 16:189-197.
48. Bratosin D, Mazurier J, Tissier JP, Estaquier J, Huart JJ, Ameisen JC,
Aminoff D, Montreuil J: Cellular and molecular mechanisms of senescent
erythrocyte phagocytosis by macrophages. A review. Biochimie 1998,
80:173-195.
49. Schlegel RA, Callahan M, Krahling S, Pradhan D, Williamson P: Mechanisms
for recognition and phagocytosis of apoptotic lymphocytes by
macrophages. Adv Exp Med Biol 1996, 406:21-28.
50. Guzik K, Potempa J: Friendly fire against neutrophils: proteolytic enzymes
confuse the recognition of apoptotic cells by macrophages. Biochimie
2008, 90:405-415.
51. Lu L, Liu H, Peng J, Gan L, Shen L, Zhang Q, Li L, Zhang L, Su C, Jiang Y:
Regulations of the key mediators in inflammation and atherosclerosis by
aspirin in human macrophages. Lipids Health Dis 2010, 9:16.
52. Kunkel SL, Spengler M, May MA, Spengler R, Larrick J, Remick D:
Prostaglandin E2 regulates macrophage-derived tumor necrosis factor
gene expression. J Biol Chem 1988, 263:5380-5384.
53. Aderem A, Underhill DM: Mechanisms of phagocytosis in macrophages.
Annu Rev Immunol 1999, 17:593-623.
54. Maderna P, Godson C: Phagocytosis of apoptotic cells and the resolution
of inflammation. Biochim Biophys Acta 2003, 1639:141-151.
55. Kim S, Elkon KB, Ma X: Transcriptional suppression of interleukin-12 gene
expression following phagocytosis of apoptotic cells. Immunity 2004,
21:643-653.
56. Lucas M, Stuart LM, Savill J, Lacy-Hulbert A: Apoptotic cells and innate
immune stimuli combine to regulate macrophage cytokine secretion. J
Immunol 2003, 171:2610-2615.
57. Leslie M: Cell biology. Beyond clotting: the powers of platelets. Science
2010, 328:562-564.
58. Page CP: Platelets as inflammatory cells. Immunopharmacology 1989,
17:51-59.
59. Katoh N: Platelets as versatile regulators of cutaneous inflammation. J
Dermatol Sci 2009, 53:89-95.
60. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME,
Massarotti EM, Remold-O’Donnell E, Farndale RW, Ware J, Lee DM: Platelets
amplify inflammation in arthritis via collagen-dependent microparticle
production. Science 2010, 327:580-583.
61. Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, Katz JA,
Fiocchi C: Platelets trigger a CD40-dependent inflammatory response in
the microvasculature of inflammatory bowel disease patients.
Gastroenterology 2003, 124:1249-1264.
62. Wagner DD, Burger PC: Platelets in inflammation and thrombosis.
Arterioscler Thromb Vasc Biol 2003, 23:2131-2137.
63. Kockx MM, Cromheeke KM, Knaapen MW, Bosmans JM, De Meyer GR,
Herman AG, Bult H: Phagocytosis and macrophage activation associated
with hemorrhagic microvessels in human atherosclerosis. Arterioscler
Thromb Vasc Biol 2003, 23:440-446.
64. Brand S: Crohn’s disease: Th1, Th17 or both? The change of a paradigm:
new immunological and genetic insights implicate Th17 cells in the
pathogenesis of Crohn’s disease. Gut 2009, 58:1152-1167.
65. Mangini AJ, Lafyatis R, Van Seventer JM: Type I interferons inhibition of
inflammatory T helper cell responses in systemic lupus erythematosus.
Ann N Y Acad Sci 2007, 1108:11-23.
66. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S: Type 17 T helper
cells-origins, features and possible roles in rheumatic disease. Nat Rev
Rheumatol 2009, 5:325-331.
67. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD,
Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E: Imiquimod-
induced psoriasis-like skin inflammation in mice is mediated via the IL-
23/IL-17 axis. J Immunol 2009, 182:5836-5845.
68. Barnes PJ: Anti-inflammatory actions of glucocorticoids: molecular
mechanisms. Clin Sci (Lond) 1998, 94:557-572.
69. McDonough AK, Curtis JR, Saag KG: The epidemiology of glucocorticoid-
associated adverse events. Curr Opin Rheumatol 2008, 20:131-137.
doi:10.1186/1476-9255-7-53
Cite this article as: Scull et al.: Macrophage pro-inflammatory cytokine
secretion is enhanced following interaction with autologous platelets.
Journal of Inflammation 2010 7:53.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Scull et al. Journal of Inflammation 2010, 7:53
http://www.journal-inflammation.com/content/7/1/53
Page 9 of 9
